Venture Partner
Zach Sweeney, Ph.D.
Background
Zach Sweeney is a Venture Partner at Versant with deep experience leading successful drug discovery groups across small molecule, biotherapeutic, and technology discovery platforms.
Previously, Zach was co-founder and CEO of Interline Therapeutics and Chief Scientific Officer of Denali Therapeutics. He has also held key drug discovery leadership roles at Genentech, Roche, Novartis, and Revolution Medicines.
Zach and his teams have contributed to the discovery and early development of over 15 drug candidates that have advanced to clinical studies. This work has been foundational to multiple company financings and licensing deals that secured more than $1B in upfront payments.
At Versant, Zach partners with academic and industry entrepreneurs to translate early-stage science into new companies and transformative medicines.
History
Zach received his B.S. in Chemistry from Stanford University and his Ph.D. in Chemistry from the University of California, Berkeley. He completed an NIH postdoctoral fellowship at Harvard University.